Date: 2014-09-12
Type of information: IPO
Company: Osmia Pharmaceutical (Sweden)
Investors:
Amount:
Funding type: IPO
Planned used:
Others: * On September 12, 2014. Oasmia Pharmaceutical announced that the company is considering a secondary listing of ADR's (American Depositary Receipts) on the United States NASDAQ stock market. Oasmia has initiated the application process, as well as filed a registration statement with the United States Securities and Exchange Commission under the JOBS Act. The company\'s shares are currently listed on NASDAQ OMX Stockholm and the Frankfurt Stock Exchange. \"The US is the largest pharmaceutical market in the world, and now that Oasmia has its first product - Paccal Vet®-CA1, for treatment of cancer in dogs - on the American market, we believe that there is an increased interest in the company among American investors. A final decision for a possible secondary listing will be made later this year\", commented Oasmia\'s CEO Julian Aleksov.
Therapeutic area: Veterinary medicine - Cancer - Oncology
